LOXL2 and idiopathic pulmonary fibrosis: Furthermore, a humanized TGFβ-neutralizing antibody (Fresolimumab) and novel inhibitors of galectin-3, LPA1, LOXL2, PDGF, and AKT are being tested in clinical trials for potential IPF treatment.